B A S E C A R E
Center for Clinical Transformation Research of Human Sperm Bank by Obstetrics & Gynecology Hospital of Fudan University and Basecare Establishing Officially
August 13,2021 · Shanghai
Opening ceremony of “Center for Clinical Transformation Research of Human Sperm Bank of Fudan University” was held in Shanghai on the morning of August 13.

With the implementation of national “three-child policy”, it’s a truth that there will be more and more older pregnant women. This puts forward higher requirement for the success rate and safety of assisted reproductive technology (ART). The critical battle for human reproductive health needs to move forward to guarantee the sperm health as a new start for all-round protection and full reproductive cycle to ensure people’s health.

To respond to the national call of “Healthy China” and “Industry-Academia-Research-Medicine”, and promote the integration of medical research institutes and industry leading enterprises, the Center for Clinical Transformation Research of Human Sperm Bank of Fudan University was established by Obstetrics & Gynecology Hospital of Fudan University and Suzhou Basecare Medical Corporation Limited (hereafter “Basecare”) jointly.
Opening ceremony of “Center for Clinical Transformation Research of Human Sperm Bank of Fudan University” was held in Shanghai on the morning of August 13.

Xu Congjian, president of Obstetrics & Gynecology Hospital of Fudan University, Hua Keqin, secretary of the Party Committee of Obstetrics & Gynecology Hospital of Fudan University, Li Xiaotian, vice president of the hospital, Zhang Feng, executive deputy director of the Human Sperm Bank of Fudan University, Jiang Feng, deputy director of the Human Sperm Bank of Fudan University, Liang Bo, president of Basecare, Kong Lingyin, R&D director of Basecare, Du Renqian, chief researcher of Basecare, and Chen Shan, chief bioinformatics officer of Basecare attended the ceremony.

At the beginning, Hua Keqin, secretary of the Party Committee of Obstetrics & Gynecology Hospital of Fudan University delivered a welcome speech. Built in 2018, Human Sperm Bank of Fudan University was the first institute that conducted whole exome gene testing and professional psychological assessment. We used genomics and phenomics technologies to evaluate the health state of sperm, preventing the pathogenic variant genes of serious diseases like birth defect from transmitting to the next generation through sperm. A high level of research institute cannot be achieved without the intersection of multiple disciplines, nor the close cooperation between institutes. I hoped that the strategic cooperation with Basecare would raise the evaluation criteria of sperm quality from the level of “external health” to “internal health” in response to national strategic principle of “Healthy China 2030”, secretary Hua said.
Professor Zhang Feng made a report on the application of genetic testing to sperm matching in the meeting, expounding the significance and importance of genetic screening applied to sperm bank with vivid examples. Through the genetic testing to the sperm donator and establishment of relevant information base, which is used to match the genetic testing result of the sperm receiver, the combination of two individuals who carry the same recessive genetic disease gene mutation can be avoided, so as to stop birth defect and promote the reproductive health.
Dr. Liang Bo introduced the background of the cooperation on the research center. As the first listed company of gene sequencing in the field of assisted reproduction, Basecare adhered to the principle of “compliant products” and became the first company that obtained Class III medical device registration certificate for PGS kit of third-generation IVF. This cooperation can effectively integrate resources of talents from universities and clinical hospitals, knowledge, technology and international cooperation to give full play to the advantages of Human Sperm Bank of Fudan University in the field of sperm research. With the R&D and industrial advantages of Basecare, we will establish an influential platform of clinical transformation and facilitate the construction of a technology innovation system dominated by the Human Sperm Bank of Fudan University and featured by tight connection of industry, academia and research, advancing the industrialization of clinical scientific payoffs, professor Liang said.
Mr. Xu, president of Obstetrics & Gynecology Hospital of Fudan University, had high expectations for the future cooperation with Basecare. Based on the strong clinical foundation and high research level in reproductive development, Fudan University incorporated talents and scientific research platform of a high level to organize a “national team of reproductive medicine”. This cooperation relationship set up a platform for technical exchange and cooperation between universities, hospitals and technology enterprises. The connection of us will realize the industrial transformation of medical research into products beneficial to patients, playing an active role in pushing the reproductive medicine development towards a leading level in the world.
New start means new journey. The start of the center for clinical transformation research will blend the rich clinical resources and solid academic innovation ability of the Obstetrics & Gynecology Hospital of Fudan University with advantages in research and development strength and industrial layout of Basecare in response to the national guideline of “medicine-academia-research-industry”. We will boost the application of technology of genetic matching, phenotype matching and genetic counseling to the sperm bank, forming a national model for clinical transformation. In the future, we will evolve a holistic solution for automated testing and storage of sperm in the center to promote the andrology strategic cooperation based on sperm genetics. Basecare will continue to expand the andrology market, in which 3.2 million families who need sperm to conceive will get benefits, and open up new markets worth CNY16 billion. Besides, birth defect of newborns in more than 60 thousand families will be reduced to make significant contributions to China’s eugenics cause.